Filtrer par catégorie
- Tous
- Congress
- Blog
- Congrès
- Ressource Scientifique
- Webinaire
- Poster
- Publication scientifique
- Communiqué de Presse
- Couverture presse
- Actualités
Filtrer par catégorie
Actualités
01/07/2021
Brand new logo for Oncodesign
Brand new logo for Oncodesign. New graphic identity with evolutive look & feel approach... First element of our new logo.
Communiqué de Presse
28/06/2021
Oncodesign launches its new DRIVE-MRT™ service offer in partnership with Covalab, CheMatech and ABX-CRO
[Press Release] Explore our brand new service offer DRIVE-MRT. it allows the rationalization, design and optimization of targeted radiopharmaceutical products that are effective against certain metastatic cancers.
Communiqué de Presse
24/06/2021
Oncodesign provides an update on its progress on RIPK2
[Press Release] Find the update of the RIPK2 program and the start of new programs associated with Nanocyclix.
Communiqué de Presse
14/06/2021
Parkinson’s disease: Servier x Oncodesign announce the selection of a preclinical candidate
Read Press Release the selection of a preclinical candidate resulting from their strategic collaboration to find new treatments for Parkinson’s disease.
Publication scientifique
12/06/2021
Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors
Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors
Publication scientifique
19/05/2021
Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models
Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models
Communiqué de Presse
18/05/2021
InterSystems & Oncodesign partner for the optimization of data use to enhance and accelerate Drug Discovery processes in oncology
Read PRess Release to have an insight on how to organize & leverage healthcare data to accelerate the search for new treatments in oncology using AI.
Webinaire
04/05/2021
[EN] Oncology and Immuno-Oncology Precision Medicine: From Hit-Finding to Pre-Clinical Candidate Selection
Novel approaches in drug discovery using innovative models (PDX & PDX-derived models) to better mimic the situation of the human cancer pathologies.
Publication scientifique
22/04/2021
ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance
Read in Communication Biologics (Nature), the data from the exoSTING preclinical program, in which Oncodesign participated (Hepa1-6).
Poster
20/04/2021
Pharmacokinetic and Biodistribution of Formatted Affimer® Biotherapeutics Targeting PD-L1
Programmed Cell Death-Ligand 1 (PD-L1) is part of the immune checkpoint system involved in preventing autoimmunity. PD-L1 is upregulated on tumors cells and binds to its receptor, PD-1, expressed by immune cells in the tumor microenvironment.
Poster
14/04/2021
Tumor-specific molecular changes in luminal B breast cancer patient-derived xenografts (PDXs) with acquired resistance to endocrine treatment
In this study we describe establishment of a luminal breast cancer PDX model with acquired resistance to hormonotherapy
Ressource Scientifique
01/04/2021
Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models
Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models